Roche Has Blockbusters In Its Pipeline – But Demurs On Predicting Hits
Flurry Of Pivotal Data In 2020
Executive Summary
Biosimilars will take a bigger bite out of revenues in 2020 but Roche should score some hits from its broad pipeline.
You may also be interested in...
Roche’s Etrolizumab Failure ‘Removes Big Pipeline Opportunity’
Roche’s etrolizumab missed primary endpoints in its Phase III study program evaluating it as maintenance therapy in moderately to severely active ulcerative colitis, a new therapeutic area for the firm.
EU Approves Takeda’s Injectable Entyvio for IBD
Takeda has won EU approval for an injectable version of Entyvio to treat ulcerative colitis or Crohn’s disease, in contrast to the FDA’s rejection in December.
Tecentriq Disappoints In Post-Surgery Bladder Cancer
Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.